Antibody immunodominance refers to the preferential and asymmetric elicitation of
antibodies against specific epitopes on a complex protein antigen. Traditional vaccination …

Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …

The high genetic diversity of hepatitis C virus (HCV) complicates effective vaccine
development. We screened a cohort of 435 HCV-infected individuals and found that 2%–5 …

The increasing incidence of hepatitis C virus (HCV) infections underscores the need for an
effective vaccine. Successful vaccines to other viruses generally depend on a long-lasting …

Vaccines that induce potent neutralizing antibody (NAb) responses against emerging
variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are essential for …

The effectiveness of SARS-CoV-2 therapeutic antibodies targeting the spike (S) receptor-
binding domain (RBD) has been hampered by the emergence of variants of concern …

Macaques are frequently used to evaluate candidate vaccines and to study infection-
induced antibody responses, requiring an improved understanding of their naïve …

Inspite of the available antiviral therapy, hepatitis C virus (HCV) remains a global health
burden and a prophylactic vaccine would help to eliminate the risk to develop chronic liver …

Introduction Early development of broadly neutralizing antibodies (bNAbs) targeting the
hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance …

Hepatitis C virus (HCV) is a serious and growing public health problem despite recent
developments of antiviral therapeutics. To achieve global elimination of HCV, an effective …